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SUMMARY Seborrheic dermatitis is a common dermatosis occurring 
on the scalp, face and chest. In the general population, the prevalence 
of seborrheic dermatitis varies between 3% and 5%, while in HIV 
positive patients there is an increased prevalence of seborrheic 
dermatitis ranging between 30% and 83%. Seborrheic dermatitis 
occurs early in the course of HIV disease and may be an initial clinical 
marker of HIV infection.
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IntRODUCtIOn 
Seborrheic dermatitis (SD) is a common chron-
ic papulosquamous dermatosis with remissions 
and exacerbations, typically located in areas with 
rich supply of sebaceous glands, i.e. the scalp, 
face and upper trunk. Clinical manifestations of the 
disease vary in severity from wild dandruff to ex-
foliative erythroderma (1-4). Many cross-sectional 
as well as cohort studies have examined the asso-
ciation between SD and human immunodeficiency 
virus (HIV) infection. We reviewed current litera-
ture regarding SD characteristics, focusing on dif-
ferences in clinical manifestations, prevalence and 
treatment between general population and HIV pa-
tients. The aim is to demonstrate that SD is more 
common, has an early onset and presents with se-
vere clinical syndrome in HIV patients, thus posing 
therapeutic difficulties in this patient population.
EpIDEMIOlOgY Of SEbORRhEIC 
DERMAtItIS
SD affects newborns, infants and adults, occurs 
in persons of all races, and the clinical syndrome 
is more severe in males than in females. The 
prevalence of SD in the general population var-
ies between 3% and 5%, increasing to 30%-83% 
in human immunodeficiency virus (HIV) positive 
and acquired immunodeficiency syndrome (AIDS) 
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patients (1,5). SD is closely related to infantile 
SD (cradle cap or diaper rash) and to neurologi-
cal disorders such as Parkinson’s disease (2,6,7). 
It is commonly worsened by changes in environ-
ment humidity, changes in seasons, trauma (e.g., 
scratching) or emotional stress (8).
EtIOlOgY Of SEbORRhEIC 
DERMAtItIS
The etiology of seborrheic dermatitis is poorly 
understood, although different lines of evidence 
support the role of Malassezia (M.) furfur (previ-
ously Pityrosporum (P.) ovale) as the causative 
yeast (9). Furthermore, the success of antifungal 
medications in treating SD provides new evidence 
for this view. Many studies describe the effective-
ness of antifungal medications, paralleled by a re-
duction in the number of P. ovale and leading to 
amelioration of SD lesions (10,11). 
Gupta et al. found M. globosa to be the pre-
dominant species in SD patients, while Sei con-
firmed the predominant presence of M. globosa 
along with M. restricta in SD patients, in contrast 
to M. sympodialis, which was detected in healthy 
skin of normal population (2,12). 
M. furfur is part of the normal resident skin flo-
ra, but under certain circumstances it may cause 
or aggravate a spectrum of skin diseases includ-
ing pityriasis vescicolor, atopic dermatitis and SD 
(13). Currently advanced laboratory methods like 
RAPD-PCR analyses can offer distinct differen-
tiation between M. furfur isolates from pityriasis 
vescicolor and SD in patients with or without AIDS 
(14). 
However, it is uncertain whether or not SD pa-
tients have higher Malassezia counts than normal 
controls (15), although a correlation between yeast 
density and severity of SD has been reported (16). 
It has been suggested that the density of Malasse-
zia organisms is only important for the individuals 
who are susceptible to SD. An abnormal immune 
response to Malassezia could be another expla-
nation. Bergbrant et al. report that in patients with 
AIDS who typically show abnormalities of T-cell 
functions, the activation of the alternative comple-
ment pathway by P. ovale which does not require 
T-cell function is depressed and could be an ex-
planation for the inflammatory response (17). 
Parry and Sharpe suggest that SD is not 
caused by an altered immune response to Mal-
assezia yeast and propose toxin production or li-
pase activity as potential mechanisms (9). Other 
researchers have shown that the lipophilic yeast 
is able to activate the alternative pathway of com-
plement (18). All the above mentioned processes 
can induce nonspecific skin inflammation. Briefly, 
a defect in immune response (specific or not) may 
facilitate fungal survival in the skin. 
Furthermore, endogenous factors have always 
been implicated in the pathogenesis of SD, along 
with others factors, e.g., the role of lipid hormones. 
The lipid amount on the skin in patients with SD 
was significantly higher than in controls (19). 
Similarly, Ostlere et al. suggest that the skin 
surface lipid composition in men with SD differs 
from that of unaffected controls (20). Since SD is 
more common in men than in women, hormones 
may play a role and androgen influence on the pi-
losebaceous unit has been suggested. In addition, 
lifestyle and nutrition may be involved in SD devel-
opment, especially in those suffering from alcohol-
ism (21) or depression (8). 
SEbORRhEIC DERMAtItIS In hIV 
InfECtED pAtIEntS
Cutaneous manifestations including SD may 
occur at any stage of HIV infection (22,23). In 
fact, the first clinical manifestations related to HIV 
infection are often located on the skin. SD is a 
common dermatosis occurring most frequently on 
the scalp, face and chest in HIV positive patients. 
In these patients, SD tends to occur early in the 
course of the disease (CD4+ T-cell count range 
450-550 cells/μL) (24-26), and is usually more se-
vere and difficult to diagnose and treat than in the 
general population (27). The butterfly distribution 
of the rash when followed by a non-diagnostic bi-
opsy, as sometimes happens, may mislead to the 
diagnosis of discoid lupus erythematosus unless 
the clinician is aware of the underlying immunode-
ficiency (26,28). Additionally, because tinea infec-
tions such as tinea faciei may occur in this patient 
population and mimic SD, a potassium hydroxide 
examination for hyphae should be performed if the 
diagnosis is in doubt (29). 
It has been shown that during the course of HIV 
disease almost 85% of patients will manifest SD at 
least once, although these data seem to be close-
ly linked to the type of the patient population and 
the duration of follow-up (31). In Mali, where SD 
is quite rare, development of this dermatosis has 
been used as a predictor for HIV infection (31,32). 
The introduction of highly active antiretroviral 
therapy (HAART) has led to a dramatic reduction 
in the incidence of opportunistic disorders and 
HIV-related mortality (30,33,34). Hengee et al. re-
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port that 25.3% of HIV patients develop SD lesions 
prior to HAART (35). In this series, the cumula-
tive incidence of SD did not change significantly 
(17.6%) among patients under HAART. In a study 
reported by Rosatelli et al., 223 HIV patients were 
examined during the 1989-1993 period, and 152 of 
these 223 patients had full-blown AIDS, whereas 
the remaining 71 patients were asymptomatic. It 
was concluded that SD was the most frequent dis-
order affecting 24% of patients in the initial stages 
of HIV and 30.3% of those with AIDS (36). 
In addition, many studies, mainly cross-sec-
tional or cohort studies, have examined the asso-
ciation between skin disease prevalence and CD4 
counts, concluding that a low CD4 cell count or 
higher viral load were linked with extended skin 
abnormalities (37-39). Also, patients suffering 
from SD and decreased CD4 cell counts were 
more likely to experience rapid progression to ad-
vanced disease (40). 
tREAtMEnt 
Antimycotics remain a popular treatment for 
SD, in the form of shampoos or creams. Many dou-
ble-blind studies have documented the efficacy of 
ketoconazole 2% in reducing flaking and Malasse-
zia counts (41,42); furthermore, ketoconazole 2% 
shampoo has been shown to have a significant 
prophylactic effect when used once weekly (11). 
Nevertheless, low potency topical corticosteroids 
(e.g., hydrocortisone) and emollients have been 
used in the initial stages of treatment (43). 
Additional measures including shampoos with 
coal tar, pyrithione zinc, then selenium sulfide and 
lithium succinate ointment may be effective treat-
ment for SD both in immunocompetent individuals 
and in those with AIDS (44). 
Newer topical successful therapeutic options 
for facial SD in HIV patients are pimecrolimus 1% 
and tacrolimus cream (45-47). These modulators 
are nonsteroid calcineurin inhibitors that exert their 
anti-inflammatory effects by inhibiting the release 
of pro-inflammatory cytokines and mediators from 
T-cells and other cells, involved in skin inflamma-
tion (48,49). 
A recent open-label pilot study conducted by 
de Moraes et al. documented that all patients re-
sponded to therapy despite their immune status 
and that pimecrolimus did not alter CD4+ and CD8+ 
T-cells counts or viral load during the treatment 
period (5). Furthermore, metronidazole has been 
used in the treatment of SD, with some promising 
results (50,51).
COnClUSIOn
SD is one of the earliest and common skin dis-
eases in the course of HIV disease. Careful ex-
amination of the skin may be highly useful for the 
diagnosis of HIV infection and the severe forms of 
common skin diseases in HIV patients (such as 
SD) may provide a clue for the clinician to suspect 
the underlying HIV infection (27,36).
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Before driving and travelling – apply Nivea cream; year 1936.
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